Sanofi ADS (SNY) Earnings Date & Reports

Key Takeaways

• Sanofi reports Q1 2026 earnings on April 23, 2026, before market open, with a webcast at 7:00 AM ET.
• Consensus estimates project sales of €10.19 billion, a modest 3% increase from €9.9 billion in Q1 2025 at constant exchange rates (CER).
• Analysts forecast EPS of $0.93 per American Depositary Share (ADS), amid focus on business EPS trends.
• Dupixent sales growth remains a key watch item, following strong Q4 2025 performance.
• 2026 guidance targets high single-digit sales growth at CER, with business EPS slightly faster.
• Sanofi shares trade near $48, below $58 analyst targets, signaling potential upside.

Earnings Context and Why It Matters

Sanofi's Q1 2026 earnings offer critical insights into the pharmaceutical giant's early-year momentum, particularly after a robust 2025 with 9.9% full-year sales growth to €43.6 billion at CER and Q4 sales of €11.3 billion, up 13.3%. Investors are watching for sustained growth in immunology franchise leader Dupixent and new launches like Ayvakit, amid seasonal vaccine softness typical for Q1. This report will gauge progress toward 2026 targets and pipeline execution in a competitive biopharma landscape, influencing stock valuation trading at a discount to peers.

Earnings Expectations

Analysts anticipate Q1 2026 sales of €10.19 billion (range €10-10.36 billion), reflecting about 3% growth at CER from €9.9 billion last year, driven by Dupixent and specialty care offsets in general medicines and vaccines. EPS consensus stands at $0.93 per ADS, with focus on business EPS (excluding select costs) after Q4's €1.53 figure. Key metrics include Dupixent quarterly sales (prior Q4 up 32.2%), new product contributions, and gross margin trends. Historically, Sanofi has beaten EPS estimates in recent quarters, like Q4 2025's $0.89 vs. $0.84 expected, though stock reactions vary.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across sectors like healthcare and pharmaceuticals. Try the AI Screener to uncover potential opportunities in biotech and beyond.

Market Reaction and Investor Sentiment

Heading into Q1 earnings, Sanofi shares hover around $48, down modestly year-to-date but up from 52-week lows, buoyed by bullish analyst sentiment with a consensus "Buy" rating and $58 price target implying over 20% upside. Positive 2026 guidance has tempered concerns, though risks include pipeline delays or currency headwinds (expected -2% sales impact). Past reactions show muted moves post-earnings, with focus shifting to guidance updates.

Forward Outlook and Key Factors to Monitor

Sanofi's reaffirmed 2026 guidance—high single-digit sales growth at CER and business EPS slightly faster—sets a baseline post-Q1, with profitability aided by share buybacks and cost discipline. Investors should track Dupixent expansion in new indications and U.S. pricing stability, alongside launches like ALTUVIIIO in hemophilia.

Vaccine seasonality may pressure Q1, but seasonal upticks later support outlook. Broader dynamics include R&D pipeline progress (e.g., immunology, rare diseases), M&A (mergers and acquisitions) activity, and forex impacts. Margin pressures from inflation or supply chains warrant attention, as does demand in emerging markets.

Upcoming catalysts include pipeline readouts and regulatory milestones, balancing competitive threats in oncology and immunology. Monitoring these will clarify trajectory toward mid-single-digit long-term growth ambitions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations